Last updated on July 2018

Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer


Brief description of study

The objective of this study is to compare the efficacy and safety of the combination therapy with enzalutamide + androgen deprivation therapy (ADT) and the combination therapy with flutamide + ADT in patients with castration resistant prostate cancer who have relapsed during combined androgen blockade (CAB) therapy with bicalutamide and ADT. This study will also investigate the order of alternative antiandrogen therapy (AAT) by changing the 1st line medication after relapse of prostate-specific antigen (PSA).

Clinical Study Identifier: NCT02918968

Contact Investigators or Research Sites near you

Start Over

Astellas Pharma Inc.

Site JP00024
Aichi, Japan

Astellas Pharma Inc.

Site JP00025
Aichi, Japan